Muscle Atrophy - Pipeline Review, H1 2018

  • ID: 4491163
  • Report
  • 36 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Escape Therapeutics Inc
  • K-Stemcell Co Ltd
  • Milo Biotechnology LLC
  • Shionogi & Co Ltd
  • Spherium Biomed SL
  • Teijin Pharma Ltd
  • MORE
Muscle Atrophy - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Muscle Atrophy - Pipeline Review, H1 2018, provides an overview of the Muscle Atrophy (Musculoskeletal Disorders) pipeline landscape.

Muscle atrophy is the wasting or loss of muscle tissue. Symptoms of muscle atrophy include muscle damage, pain, weak muscles, loss of movement, facial weakness and numbness or tingling in arms or legs. Causes include aging, nerve diseases, stroke, motor neuropathy, muscular dystrophy and arthritis. Treatment includes exercise, dietary changes and surgery.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Muscle Atrophy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Muscle Atrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Muscle Atrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscle Atrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Unknown stages are 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Muscle Atrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Muscle Atrophy (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Muscle Atrophy (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Muscle Atrophy (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Muscle Atrophy (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Muscle Atrophy (Musculoskeletal Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Muscle Atrophy (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Muscle Atrophy (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Escape Therapeutics Inc
  • K-Stemcell Co Ltd
  • Milo Biotechnology LLC
  • Shionogi & Co Ltd
  • Spherium Biomed SL
  • Teijin Pharma Ltd
  • MORE
Introduction

Report Coverage

Muscle Atrophy - Overview

Muscle Atrophy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Muscle Atrophy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Muscle Atrophy - Companies Involved in Therapeutics Development

Escape Therapeutics Inc

K-Stemcell Co Ltd

Milo Biotechnology LLC

Shionogi & Co Ltd

Spherium Biomed SL

Teijin Pharma Ltd

Muscle Atrophy - Drug Profiles

AAV9-Follistatin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EMMY-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EMMY-106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FibroStem - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JP4-039 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit HSD11B1 for Muscle Atrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SP-15028 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Parry-Romberg disease and Thromboangiitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TEISARM-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Muscle Atrophy - Dormant Projects

Muscle Atrophy - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Muscle Atrophy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Muscle Atrophy - Pipeline by Escape Therapeutics Inc, H1 2018

Muscle Atrophy - Pipeline by K-Stemcell Co Ltd, H1 2018

Muscle Atrophy - Pipeline by Milo Biotechnology LLC, H1 2018

Muscle Atrophy - Pipeline by Shionogi & Co Ltd, H1 2018

Muscle Atrophy - Pipeline by Spherium Biomed SL, H1 2018

Muscle Atrophy - Pipeline by Teijin Pharma Ltd, H1 2018

Muscle Atrophy - Dormant Projects, H1 2018

Muscle Atrophy - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Muscle Atrophy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Escape Therapeutics Inc
  • K-Stemcell Co Ltd
  • Milo Biotechnology LLC
  • Shionogi & Co Ltd
  • Spherium Biomed SL
  • Teijin Pharma Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll